CABA

Cabaletta Bio INC

+$63.8M

Net Activity

Institutions Holding

112

Popularity Rank

#4215

Avg Weight

0.07%

Total Value

$233.9M

Ownership Trend

112 institutions currently hold CABA, with 61 net buyers and 38 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Increased

Based on recent trading activity

Net Selling Institutions

38

Net Buying Institutions

61

Key Holders

View all 112 holding institutions

Quarterly Activity

Recent Activity

+$148.9M

Total Buy Value

$19.7M

Total Sell Value

New buy26
Trim27
Add35
Sold out11

61

Net Buyers

38

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding CABALETTA BIO INC (CABA)?
Major stakeholders currently include T. Rowe Price Investment Management, Inc. ($29.8M), Bain Capital Life Sciences Investors, LLC ($26.0M), Jennison Associates LLC ($24.1M). Based on the latest 13F filings, there are a total of 112 tracked investment funds and institutions maintaining positions in CABA.
What is the overall institutional sentiment toward CABA recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $63.8M, driven by 61 managers accumulating shares while 38 reduced their exposure.
Which institutions have been selling or reducing their CABA positions?
In the latest period, 27 funds trimmed their holdings, and 11 managers completely exited their positions. The aggregate reported sell value was $19.7M.
Are there any notable investors adding CABA to their portfolios?
Yes, buying activity remains notable. 26 institutions opened new positions in {ticker}, and 35 existing holders added to their shares. The total reported buy value for the quarter amounted to $148.9M.

Related Stocks